The Pfizer Covid vaccine was found to be 100% effective in stopping serious illness from the coronavirus in 12-15 year olds.
Most Covid-19 vaccines launched worldwide are aimed at the elderly, who are at higher risk of death from the virus.
In the UK, those most affected by health problems have been prioritized along with a sliding age scale starting in the 1980s and working its way through the population as a whole.
Pfizer’s vaccine, also known as the Pfizer BioNTech vaccine, has been approved in the US for over 16 years but has yet to be given en masse to younger people as more trial results have been gathered.
In a study of 2,260 U.S. volunteers ages 12-15, preliminary data showed no cases of Covid-19 in fully vaccinated teens, compared to 18 in placebo shots, Pfizer said in a statement this morning.
Albert Bourla, Pfizer Chairman and Chief Executive Officer, said: “We share the urgency to expand our vaccine approval for use in younger populations and are encouraged by clinical trial data from adolescents 12-15 years of age.
“We plan to submit this data to the FDA and other regulatory agencies around the world as a proposed amendment to our emergency clearance in the coming weeks in the hopes of starting vaccination for this age group before the start of the next school year.”
The researchers reported high levels of virus-fighting antibodies in the children vaccinated in the study, higher than in studies in young adults.
And according to the company, the vaccinated children had side effects similar to those of young adults who suffered from the bite, such as arm pain, chills and fatigue.
Pfizer and its German partner BioNTech plan to request the US Food and Drug Administration and European regulatory authorities in the coming weeks to authorize the use of the vaccine from the age of 12 in an emergency.
Last week, companies released the first doses of the vaccine in a series of studies testing the vaccine in younger children who will eventually go to children as young as 6 months of age.